Everything below concerns bremelanotide. We keep the language plain, cite what the science says, and separate well-supported claims from open questions.
Updated 2026-01-23. Numbers and descriptions here follow the published literature rather than marketing material.
Bremelanotide is a synthetic cyclic heptapeptide developed under the research code PT-141. The code reflects its position in an internal compound series rather than a chemical classification, and the name bremelanotide was later adopted for regulatory filings. Structurally it belongs to the melanocortin peptide family and shares a core sequence motif with alpha-melanocyte-stimulating hormone. The compound is supplied as an acetate salt in aqueous solution for injection. In reference literature it is indexed under both the code and the generic name, a dual listing that can complicate database searches.
Early work on melanocortin analogs in the 1980s and 1990s produced peptides intended to influence pigmentation and appetite. One of these, melanotan II, was observed to affect sexual desire as an incidental finding in self-administration reports. Researchers then pursued analogs with altered receptor selectivity and improved handling characteristics, and PT-141 emerged from that program in the late 1990s. The development path moved from dermatology and metabolism toward a central nervous system application, a shift that shaped both trial designs and the eventual label.
Bremelanotide is a synthetic cyclic heptapeptide that acts on a family of G-protein-coupled receptors. It was designed as a structural analogue of alpha-melanocyte-stimulating hormone, the endogenous peptide associated with pigmentation and several central signalling pathways. A lactam bridge constrains the ring and slows enzymatic breakdown, which distinguishes it from the linear parent molecule. Research interest moved over time from pigment biology toward central nervous system effects, particularly circuits connected to sexual desire. Parenteral delivery is used because oral bioavailability is poor.
Early clinical work used an intranasal formulation, and later programmes switched to subcutaneous delivery for more consistent absorption. A subcutaneous product received regulatory approval in the United States in 2019 for premenopausal women with acquired, generalised hypoactive sexual desire disorder. Approval followed phase 3 trials in which active treatment separated from placebo on desire and distress measures, though the average difference was modest. Labeling carries a caution about transient blood pressure elevation, so cardiovascular history is assessed before prescribing. Questions about durability of benefit beyond several months remain open.
| Property | Value | Notes |
|---|---|---|
| Molecular formula | C50H68N14O10 | Cyclic heptapeptide core |
| Molecular weight | 1025.2 g/mol | Calculated for the free base |
| CAS registry number | 189691-06-3 | Free base; the acetate salt has a separate entry |
| Solubility class | Water-soluble | Freely soluble in aqueous media near neutral pH |
| Typical storage | 2 to 8 °C | Protect from light; avoid repeated freeze-thaw cycles |
Routine characterisation of bremelanotide relies on reversed-phase high-performance liquid chromatography with ultraviolet detection near 214 nm, where the peptide backbone absorbs. Mass spectrometry, typically in tandem mode with electrospray ionisation, confirms identity and supports quantification in biological matrices. Additional checks include amino acid analysis, peptide mapping after enzymatic digestion, and confirmation of the lactam bridge, since incomplete cyclisation produces a mass-shifted by-product. Purity values above 95 percent are common in reference-grade material, though reports vary in how strictly related substances are resolved from the parent peak.
The lyophilised solid is relatively stable when kept dry, protected from light and held at reduced temperature, commonly minus 20 degrees Celsius or lower for long-term storage. In solution the peptide is more vulnerable: tryptophan oxidation, hydrolysis of the lactam bridge and aggregation all become relevant over time, and the rate depends on pH, buffer composition and concentration. Repeated freeze-thaw cycles are generally avoided because they promote aggregation. Aqueous working solutions are typically prepared fresh or split into single-use aliquots to limit degradation before analysis.
Clinical programmes in this area have relied mainly on randomised, double-blind, placebo-controlled designs in premenopausal women. Primary endpoints usually combine a validated questionnaire covering desire domains with counts of satisfying sexual events and a separate measure of distress. Reported outcomes show statistically significant but modest average improvement over placebo, with wide individual variation. Adverse events such as nausea, flushing, and headache occur frequently and can limit tolerability. Whether short-term trial gains translate into lasting change for most users is an open question.
Evidence outside the studied population is sparse. Trials have concentrated on premenopausal women with a defined diagnosis, and data for postmenopausal women, men, and people taking interacting medications remain limited. Non-prescription use of the peptide for comparable goals is widespread but is not supported by published controlled data. Observed changes in blood pressure have drawn attention to cardiovascular monitoring during use. The literature generally frames the compound as a targeted receptor agonist rather than a general libido enhancer, and basic questions about mechanism and long-term safety are unresolved.
=== Physical and atomic === Meitnerium is expected to be a solid under normal conditions and assume a face-centered cubic crystal structure, similarly to its lighter congener iridium. It should be a very heavy metal with a density of around 27–28 g/cm3, which would be among the highest of any of the 118 known elements. Meitnerium is also predicted to be paramagnetic. Theoreticians have predicted the covalent radius of meitnerium to be 6 to 10 pm larger than that of iridium. The atomic radius of meitnerium is expected to be around 128 pm.
The cell's energy is equal to the voltage times the charge. Each gram of lithium represents Faraday's constant / 6.941(atomic mass), or 13,901 coulombs. At 3 V, this gives 41.7 kJ per gram of lithium, or 11.6 kWh per kilogram of lithium. This is slightly more than the heat of combustion of gasoline; however, lithium-ion batteries as a whole are still significantly heavier per unit of energy due to the additional materials used in production. Note that the cell voltages involved in these reactions are larger than the potential at which an aqueous solutions would electrolyze.
Peña suspended negotiations with Brazil on the revision of Annex C of the Itaipu Treaty, alleging a supposed case of digital espionage by Brazilian authorities between 2022 and 2023. Critical sectors pointed out that the suspension favored Brazil by keeping frozen a key process to correct what they consider a historic disadvantage for Paraguay in the distribution of the benefits of hydroelectricity generated by Itaipu Binacional.
Sources: en.wikipedia.org
The country now known as Zimbabwe was formally known as Southern Rhodesia from 1895 to 1980—although simply Rhodesia was used locally between 1964 until June 1979 after Northern Rhodesia obtained its independence—and then Zimbabwe Rhodesia between June and December 1979. Southern Rhodesia achieved responsible government in 1923, and thereby became a British self-governing colony following three decades of rule by the British South Africa Company. Following the granting of responsible government, a flag was adopted which followed the standard British colonial practice, being a Blue Ensign, defaced with the shield from the Southern Rhodesian coat of arms. This basic design was used until 1968, although a light blue ensign was introduced in April 1964 following the break-up of the Federation of Rhodesia and Nyasaland. On 11 November 1968, three years after the predominantly white government unilaterally declared independence from Britain, a national flag based on a completely new design was adopted. This was a green-white-green vertical triband, charged centrally with the national coat of arms. It was the first national flag to contain the Zimbabwe Bird, which had been present in the coat of arms since 1924. In 1979, when the country reconstituted itself as Zimbabwe Rhodesia following the Internal Settlement between the government and moderate black nationalists, a new flag was adopted to mark the transition on 4 September of that year.
While not as life-threatening as a bite from a venomous species, the bite can be at least temporarily debilitating and could lead to dangerous infections if improperly dealt with. While most snakes must open their mouths before biting, African and Middle Eastern snakes belonging to the family Atractaspididae can fold their fangs to the side of their head without opening their mouth and jab a person.
Bacterial Inclusion Bodies Contain Amyloid-Like Structure at SciVee Amyloid Cascade Hypothesis Amyloid: Journal of Protein Folding Disorders web page Role of anesthetics in Alzheimer's disease: Molecular details revealed
Sources: en.wikipedia.org
Sex hormone-binding globulin (SHBG) Sex steroid-binding globulin (SSBG, SBG) Sex steroid-binding protein (SBP, SSBP) Androgen-binding protein (ABP) Estradiol-binding-protein (EBP) Testosterone–estradiol binding globulin (TeBG, TEBG)
=== Animal === Laboratory tests assessing the toxicity of chlordiazepoxide, nitrazepam and diazepam on mice spermatozoa found that chlordiazepoxide produced toxicities in sperm including abnormalities involving both the shape and size of the sperm head. Nitrazepam, however, caused more profound abnormalities than chlordiazepoxide.
=== SCIRI === The organization was formed in Iran in 1982 as the military wing of the Supreme Council for Islamic Revolution in Iraq. It was based in Iran for two decades during the rule of Saddam Hussein and led by Iranian officers. It consisted of several thousand Iraqi exiles, refugees, and Iraqi Army defectors who fought alongside Iranian troops in the Iran–Iraq War. The group was armed and directed by Iran. They briefly returned to Iraq in 1991 during the 1991 Iraqi uprising to fight against the government of Saddam Hussein, focusing on the Shia holy cities of Najaf and Karbala. They retreated into Iran after the uprising was brutally crushed by the Ba'athist regime. In 1995, during the Iraqi Kurdish Civil War, Iran deployed 5,000 Badr fighters to Iraqi Kurdistan to support the PUK forces.
Barnsley won the 2006 League One play-off final and remained in the Championship for eight seasons. Relegated in 2014, they won both the 2016 Football League Trophy final and the 2016 League One play-off final, though this time spent just two seasons in the Championship. In 2017, a majority stake in the club was sold to a consortium that included Chien Lee, Neerav Parekh and Billy Beane. Barnsley won promotion from League One with a second-place finish in the year 2019, before being relegated out of the Championship again in the year of 2022. Barnsley have spent more seasons and played more games at the second level of English football than any other team. The club's main rivals are fellow Yorkshire clubs Sheffield Wednesday, Sheffield United, Leeds United, Huddersfield Town and Rotherham United.
Sources: en.wikipedia.org
PT-141 was the internal development code assigned to bremelanotide during preclinical research. Reference sources sometimes index the peptide under the code rather than the generic name. The two terms describe the same molecule.
They are related but distinct cyclic peptides. Melanotan II is an earlier and less selective melanocortin analog. Bremelanotide was developed later with a narrower receptor profile and a defined clinical application.
The reviewed product is given by subcutaneous injection using a single-use autoinjector. Administration occurs under prescription supervision. The device delivers one fixed amount per use rather than a measured or adjustable quantity.
It is a synthetic cyclic peptide that activates melanocortin receptors. It is given by injection and was approved in the United States in 2019 for a specific low-desire diagnosis in premenopausal women. It is not a hormonal therapy.